Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Collection of Positive Control Samples for T-cell Immune Function to SARS-CoV-2 after COMIRNATY Vaccination
jRCT1051250086Completed
- Sponsor
- VLP Therapeutics Japan
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by VLP Therapeutics Japan. Started Aug 2025; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1051250086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051250086.